SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D. C.  20549

                                  ____________



                                    FORM 8-K



                                 CURRENT REPORT



                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                          DATE OF REPORT: JULY 18, 2000
                        (Date of earliest event reported)


                              INCYTE GENOMICS, INC.
                     (FORMERLY INCYTE PHARMACEUTICALS, INC.)
             (Exact name of registrant as specified in its charter)


               DELAWARE                      0-27488         94-3136539
         (State or other jurisdiction      (Commission     (IRS Employer
           of incorporation)               File Number)    Identification
                                                                No.)


           3160 PORTER DRIVE, PALO ALTO, CALIFORNIA              94304
           (Address of principal executive offices)             (Zip Code)


       Registrant's telephone number, including area code:  (650) 855-0555



Item  5.     Other  Events.
             -------------

     Attached hereto as Exhibit 99.1 and incorporated by reference herein is the
press  release  dated  July 18, 2000 announcing that Incyte's board of directors
have  approved a two-for-one stock split in the form of a stock dividend. Incyte
stockholders  of  record at the close of business on August 7, 2000 will receive
one  additional  share  for  each  share  of  common stock held at the time. The
additional  shares  will  be  distributed to eligible stockholders on August 31,
2000.

Item  7.  Financial  Statements  and  Exhibits.
          ------------------------------------

     (c)     Exhibits

99.1     Press  release  dated  July  18,  2000.



                                    SIGNATURE


     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  hereunto  duly  authorized.


                                 Dated:  July  18,  2000

                                 INCYTE  GENOMICS,  INC.

                                 By    /s/  John  M.  Vuko
                                       -------------------
                                       Name:  John  M.  Vuko
                                       Title: Executive  Vice  President  and
                                       Chief  Financial  Officer